AU754242B2 - Method of treating HIV infection and related secondary infections thereof - Google Patents

Method of treating HIV infection and related secondary infections thereof Download PDF

Info

Publication number
AU754242B2
AU754242B2 AU71609/98A AU7160998A AU754242B2 AU 754242 B2 AU754242 B2 AU 754242B2 AU 71609/98 A AU71609/98 A AU 71609/98A AU 7160998 A AU7160998 A AU 7160998A AU 754242 B2 AU754242 B2 AU 754242B2
Authority
AU
Australia
Prior art keywords
disease
therapeutic compound
defibrotide
marker
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU71609/98A
Other languages
English (en)
Other versions
AU7160998A (en
Inventor
Arsinur Burcoglu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU7160998A publication Critical patent/AU7160998A/en
Application granted granted Critical
Publication of AU754242B2 publication Critical patent/AU754242B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU71609/98A 1997-04-28 1998-04-28 Method of treating HIV infection and related secondary infections thereof Ceased AU754242B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84801397A 1997-04-28 1997-04-28
US848013 1997-04-28
PCT/US1998/008357 WO1998048843A1 (en) 1997-04-28 1998-04-28 Method of treating hiv infection and related secondary infections thereof

Publications (2)

Publication Number Publication Date
AU7160998A AU7160998A (en) 1998-11-24
AU754242B2 true AU754242B2 (en) 2002-11-07

Family

ID=25302109

Family Applications (1)

Application Number Title Priority Date Filing Date
AU71609/98A Ceased AU754242B2 (en) 1997-04-28 1998-04-28 Method of treating HIV infection and related secondary infections thereof

Country Status (5)

Country Link
EP (1) EP1202750A4 (zh)
AU (1) AU754242B2 (zh)
CA (1) CA2259041A1 (zh)
HK (1) HK1044896A1 (zh)
WO (1) WO1998048843A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2358385C (en) 1998-12-31 2013-08-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1411770A4 (en) 2001-07-05 2006-05-10 Chiron Corp POLYNUCLEOTIDES CODING FOR ANTIGENIC C-TYPE HIV POLYPEPTIDES, POLYPEPTIDES AND THEIR USE
CN1304011C (zh) * 2002-05-31 2007-03-14 雷根斯堡大学医学院 保护性寡聚脱氧核糖核苷酸的制药用途
ITMI20031714A1 (it) * 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.
EP1718150A1 (en) * 2004-02-25 2006-11-08 The Government of the United States of America, represented by the Secretary, Department of Health and Human Services Methylation inhibitor compounds
AU2007231651B2 (en) * 2005-03-03 2011-09-15 Gentium Spa Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors
KR20070120953A (ko) * 2005-03-03 2007-12-26 젠티엄 에스피에이 항암활성을 갖는 제제
ITMI20050336A1 (it) * 2005-03-03 2006-09-04 Gentium Spa Formulazione ad attivita' anti-tumorale
DK2637672T3 (en) 2010-11-12 2018-10-22 Gentium S R L DEFIBROTID FOR USE IN PROPHYLAXY AND / OR TREATMENT OF GRAPHIC VERSUS HOST DISEASE (GVHD)
KR20190112197A (ko) 2012-06-22 2019-10-02 젠티엄 에스알엘 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649134A (en) * 1983-09-12 1987-03-10 Crinos Industria Farmacobiologica Spa Pharmaceutical composition containing defibrotide for the treatment of states of acute renal insufficiency
US4693995A (en) * 1984-02-16 1987-09-15 Crinos Industria Farmacobiologica S.P.A. Pharmaceutical composition for the treatment of acute myocardial ischemia
US5081109A (en) * 1983-09-12 1992-01-14 Crinos Industria Farmacobiolgica Spa Pharmaceutical composition and method for the therapy of peripheral arteriopathies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991017246A1 (en) * 1990-05-04 1991-11-14 Isis Pharmaceuticals, Inc. Modulation of gene expression through interference with rna secondary structure
IT1252174B (it) * 1991-12-09 1995-06-05 Crinos Industria Farmaco Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento
AU692433B2 (en) * 1993-01-13 1998-06-11 Arsinur Burcoglu Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
WO1995004068A1 (en) * 1993-07-29 1995-02-09 Isis Pharmaceuticals, Inc. Oligomers for modulating human immunodeficiency virus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649134A (en) * 1983-09-12 1987-03-10 Crinos Industria Farmacobiologica Spa Pharmaceutical composition containing defibrotide for the treatment of states of acute renal insufficiency
US5081109A (en) * 1983-09-12 1992-01-14 Crinos Industria Farmacobiolgica Spa Pharmaceutical composition and method for the therapy of peripheral arteriopathies
US4693995A (en) * 1984-02-16 1987-09-15 Crinos Industria Farmacobiologica S.P.A. Pharmaceutical composition for the treatment of acute myocardial ischemia

Also Published As

Publication number Publication date
WO1998048843A1 (en) 1998-11-05
HK1044896A1 (zh) 2002-11-08
AU7160998A (en) 1998-11-24
EP1202750A4 (en) 2002-10-16
CA2259041A1 (en) 1998-11-05
EP1202750A1 (en) 2002-05-08

Similar Documents

Publication Publication Date Title
US6699985B2 (en) Method of treating HIV infection and related secondary infections thereof
TWI823866B (zh) 用於抑制類血管生成素蛋白-3(ANGPTL3)表現的RNAi藥劑及組合物及使用方法
US5977083A (en) Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
US9932586B2 (en) Compositions and methods for inhibiting gene expression of LPA
EP1931806B1 (en) Pkr activation via hybridization chain reaction
US20070161587A1 (en) Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof
AU754242B2 (en) Method of treating HIV infection and related secondary infections thereof
JPH10507635A (ja) 遺伝子発現をダウンレギュレートするための２’−置換オリゴヌクレオチドの使用
JP2021529173A (ja) Ｒｉｇ−ｉアゴニストおよびそれを使用した処置
US11939581B2 (en) Methods and compositions for targeting PD-L1
US5624912A (en) Method of treating HIV infection and related secondary infections with defibrotide
AU692433B2 (en) Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
Goulaouic et al. Exogenous nucleosides promote the completion of MoMLV DNA synthesis in G0-arrested Balb c/3T3 fibroblasts
WO2001011023A1 (en) Treatment of inflammatory or malignant disease using dnazymes
WO2003025139A2 (en) Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof
US6342485B1 (en) Synergistic compositions useful as anti-tumor agents
RU2112766C1 (ru) Олигонуклеотиды, фармацевтическая композиция
JP2016192963A (ja) 腫瘍細胞の生存を低下させるｙｂ−１アンチセンスオリゴヌクレオチド
CN114574496B (zh) 核苷类衍生物改性的核酸适体sgc8
KR102061924B1 (ko) Ｐ３２ 저해제를 포함하는 심혈관 질환 예방 또는 치료용 조성물
EP0747386A2 (en) Method and antisense oligonucleotides to Interleukin-6 receptor mRNA for inhibiting cellular proliferation
Uhlmann Oligonucleotide technologies: synthesis, production, regulations and applications
CN111321159A (zh) 用于免疫调节的嵌合核酸分子及其应用
CN111154755B (zh) 一种双链寡核苷酸dna及其应用
Agrawal Antisense oligonucleotide-based therapy for HIV-1 infection from laboratory to clinical trials

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)